曲美他嗪在心血管疾病中的研究进展

The Progress of Trimetazidine in Cardiovascular Disease

心血管疾病在全世界范围内的发病率越来越高,当前的药物治疗、介入治疗虽能缓解疾病的症状、减缓疾病的进展,但心血管疾病的死亡率仍然很高。研究表明能量代谢调节剂曲美他嗪(TMZ)能够使稳定型心绞痛、急性冠脉综合征、糖尿病性心肌病、心力衰竭、心肌纤维化等心血管疾病患者受益。

The incidence of cardiovascular diseases is higher and higher in the global.The mortality of cardiovasclar diseases is still high although the current treatments,such as drug treatment and interventional treatment can improve the symptoms and delay the progress of the diseases.The metabolic regulator trimetazidine（TMZ）was benefit to patients with cardiovascular diseases such as stable angina pectoris,aucte coronary syndrame,diabetes cardiomyopathy,heart failure,myocardial fibrosis and so on.